ClinicalTrials.Veeva

Menu

Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21

U

UNC Nutrition Research Institute

Status

Completed

Conditions

Insulin Sensitivity

Treatments

Dietary Supplement: Betaine
Dietary Supplement: Dextrose

Study type

Interventional

Funder types

Other

Identifiers

NCT02118142
13-2548

Details and patient eligibility

About

People with poor insulin sensitivity do not respond normally to elevations in blood sugar. This may increase their risk of developing diabetes in the future. The purpose of this research study is to determine if the nutrient betaine, found in beets, spinach and wheat products, can enhance the production of fetal growth factor 21 (FGF21), a molecule that is believed to promote insulin sensitivity.

Full description

AIM: To determine if betaine is a modulator of FGF21 in humans. Low plasma betaine is associated with an increased risk of metabolic syndrome, but the mechanisms modulating this correlation are poorly delineated. Betaine bioavailability in humans is determined by dietary intake and genetic polymorphisms that influence betaine metabolism. Therefore, moderating betaine levels could be particularly beneficial for some individuals. FGF21 is elevated in response to insulin insensitivity and is under active investigation as a therapeutic modality. The mechanisms of action of FGF21 and betaine on insulin sensitivity in humans are incompletely understood. This study tests the hypothesis that betaine induces FGF21 secretion and insulin sensitizing actions in humans by measuring plasma FGF21, betaine, choline (betaine precursor), glucose, insulin and adiponectin in response to betaine supplementation over a 24 hour time course in 20 healthy, lean individuals. This pilot nutrition intervention will provide key preliminary evidence for understanding whether and how betaine exerts metabolic benefit in humans and will inform a future study to investigate the novel betaine-FGF21-insulin sensitivity axis in a larger cohort.

Enrollment

23 patients

Sex

All

Ages

21 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy
  • Able/willing to consume study meals
  • Non-smoker
  • BMI in normal range (18-24.9)

Exclusion criteria

  • Use of chronic medications
  • Abnormal physical examination or chronic illness
  • Use of drugs or medications known to alter choline/betaine metabolism
  • Consumption of more than 2 oz of alcohol/day or 24 oz wine/day
  • Use of choline/betaine-containing dietary supplements during the previous 3 months
  • Diagnosed with Cystathionine Beta-Synthase (CBS) Deficiency
  • Pregnant or breastfeeding
  • Known hypersensitivity to betaine
  • Current substance abuse or addiction

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

23 participants in 2 patient groups, including a placebo group

Betaine
Active Comparator group
Description:
6 gram dose of betaine delivered in encapsulated form
Treatment:
Dietary Supplement: Betaine
Dextrose
Placebo Comparator group
Description:
6 gram dose of dextrose delivered in encapsulated form
Treatment:
Dietary Supplement: Dextrose

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems